CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vertex Pharmaceuticals Incorporated is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Phone: (617) 341-6393p:617 341-6393 BOSTON, MA  02210  United States Ticker: VRTXVRTX
Business Summary
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Jeffrey M.Leiden 67 4/1/2020 7/6/2009
President, Chief Executive Officer, Director ReshmaKewalramani 50 4/1/2020 4/1/2018
Chief Financial Officer, Executive Vice President Charles F.Wagner 55 4/10/2019 4/10/2019
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Vertex Pharmaceuticals (Europe) Limited 2 Kingdom Street London England United Kingdom
Vertex Pharmaceuticals (Canada) Incorporated 275 Boulevard Armand Frappier Laval QC Canada

Business Names
Business Name
Company for Services and Trade VERTEX PHARMACEUTICALS DOOEL Skopje
Encap, Inc.
Macedonian company
36 additional Business Names available in full report.

General Information
Number of Employees: 5,400 (As of 12/31/2023)
Outstanding Shares: 258,459,343 (As of 3/18/2024)
Shareholders: 106
Stock Exchange: NASD
Federal Tax Id: 043039129


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024